The Miami Debates in Hematologic Malignancies

Date : 27th January 2022 to 27th January 2022

Place : Israel, Jerusalem

Website :https://mdhm2022.com/

Contact Person:Rosemarie Dotorovici Liberman

Description:

It is our great pleasure to welcome you to The Miami Debates in Hematologic Malignancies virtual conference which will take place on January 27, 2022. The aims of the conference are to provide an up-to-date review of the latest news in the field of hematologic malignancies. The content of the meeting will focus on clinical management. Also, novel scientific data will be reviewed and discussed from a clinical perspective. The format of the meeting will be a combination of focused lectures and debates centered around controversial topics. We will bring together international leaders in the field of clinical hematology and oncology to debate and deliver talks that are idea-focused, from the basic mechanisms to the present and future therapies. The Conference will focus on the following key areas: Optimal treatments for newly diagnosed and relapsed patients Bispecific and conjugated monoclonal antibodies Chemotherapy-free treatments Minimal residual disease (MRD) testing in the clinic CAR T cell and CAR NK cell therapies Future role of bone marrow transplant New drugs in development This Conference will welcome hematologists, oncology professionals, physicians, health care professionals, treatment experts, clinical research organizations, CRO’s, industry leaders and other experts. Share your research by submitting an abstract for e-poster presentation. Join us as a Sponsor and benefit from maximum visibility and exposure to a broader audience. We look forward to meeting you online at The Miami Debates in Hematologic Malignancies! C. Ola Landgren M.D., Ph.D. Conference Chair

The Miami Debates in Hematologic Malignancies will be held in Jerusalem,Israel on date 2022-01-27

---

Deadline for abstracts/proposals : 30th November 2021

Keynote Speakers :

Conference Highlights :Optimal treatments for newly diagnosed and relapsed patients Bispecific and conjugated monoclonal antibodies Chemotherapy-free treatments Minimal residual disease (MRD) testing in the clinic CAR T cell and CAR NK cell therapies Future role of bone marrow transplant New drugs in development

Check the event website for more details.